SCHEMBL6368024

SCHEMBL6368024

Cc1cccc(CC#N)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
GRIA1 P42261 1/20 0.36
CACNG8 Q8WXS5 1/20 0.36
CYP2D6 P10635 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX12 P18054 1/20 0.35
CYP2C19 P33261 1/20 0.35
TSHR P16473 1/20 0.34
CYP2A6 P11509 1/20 0.34
P2RX7 Q99572 5/20 0.34
SLC6A4 P31645 2/20 0.33
PNMT P11086 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8660405 0.85 ALDH1A1 (0.44) ALDH1A1HPGDGRIA1CACNG8CYP2D6
SCHEMBL16952334 0.80 GABRA1 (0.38) ALDH1A1CYP2D6P2RX7SLC6A4PNMT
SCHEMBL29763190 0.79 PNMT (0.56) ALDH1A1HPGDGRIA1CACNG8CYP2D6
SCHEMBL3792645 0.79 ESR1 (0.41) ALDH1A1HPGDMEN1KMT2ACYP1A2
SCHEMBL310847 0.79 PNMT (0.56) ALDH1A1HPGDGRIA1CACNG8CYP2D6
Water SCHEMBL28641184 0.79 ALDH1A1 (0.47) ALDH1A1HPGDMEN1KMT2ACYP1A2
SCHEMBL31426960 0.79 ALDH1A1 (0.47) ALDH1A1HPGDMEN1KMT2ACYP1A2
SCHEMBL102904 0.79 ALDH1A1 (0.47) ALDH1A1HPGDMEN1KMT2ACYP1A2
SCHEMBL28380698 0.78 ALDH1A1 (0.45) ALDH1A1HPGDGRIA1CACNG8MEN1
SCHEMBL8763095 0.78 ALDH1A1 (0.39) ALDH1A1HPGDGRIA1CACNG8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6838478-B2 Amino acid derivatives and their use as thrombin inhibitors ASTRAZENECA AB (SE) 2005-01-04 US disclosed
CN-1129604-C Amino acid derivatives and their use as thrombin inhibitors ASTRA AB (SE) 2003-12-03 CN disclosed
EP-0910573-B1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRAZENECA AB (SE) 2003-01-29 EP disclosed
US-20020019371-A1 New amino acid derivatives and their use as thrombin inhibitors ASTRAZENECA AB 2002-02-14 US disclosed
US-6255301-B1 CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS ASTRAZENECA AB (SE) 2001-07-03 US disclosed
CN-1226895-A Amino acid derivatives and their use as thrombin inhibitors ASTRA AB (SE) 1999-08-25 CN disclosed
EP-0910573-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS Astra Aktiebolag (SE) 1999-04-28 EP disclosed
WO-1997046577-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRA AKTIEBOLAG (SE) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019371-A1 New amino acid derivatives and their use as thrombin inhibitors F2, SERPINC1, FGB ALDH1A1 4222/4885HPGD 2067/4885GRIA1 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.